Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases
GAITHERSBURG, MD, September 30, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the Department of Defense (DoD) has awarded the company an additional $8 million for the continued development of bacteriophage therapies (PhageBankTM) for the treatment of infectious diseases. The new funding brings the total contract awarded to APT to $31.2 million.
URL link to full story
https://www.aphage.com/adaptive-phage-therapeutics-awarded-additional-8-million-from-u-s-department-of-defense-for-clinical-advancement-of-phage-to-address-unmet-needs-in-infectious-diseases/
Media Contact
Laurence Watts
619-916-7620